Pharmaceutical intelligence for NeuroBiogen Co., Ltd. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 1

Recent signals(1)

ClinicalJune 23, 2026

Phase 2a Trial of KDS2010 in Obesity Shows Promising Efficacy and Safety Profile

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 23, 2026

Phase 2a Trial of KDS2010 in Obesity Shows Promising Efficacy and Safety Profile

Competitive activity

No signals indexed for this entity yet.

Assets

KDS2010 →

Therapeutic areas

Obesity →

Small Molecule →

Indications

Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.